As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.
18 Analysts have issued a Cogent Biosciences Inc forecast:
18 Analysts have issued a Cogent Biosciences Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -286 -286 |
27%
27%
|
EBIT (Operating Income) EBIT | -288 -288 |
27%
27%
|
Net Profit | -202 -202 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Andrew Robbins |
Employees | 205 |
Founded | 2014 |
Website | www.cogentbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.